News >

Higher Distress Scores Linked With Lower Survival in Myeloma

Danielle Bucco
Published: Wednesday, Feb 07, 2018

John Richter, MD

Joshua R. Richter, MD
With several new agents entering the treatment landscape, patients with multiple myeloma are facing different toxicity, financial, and psychological burdens. As a chronic disease, additional attention is needed to address these issues and improve patients’ overall quality of life, according to Joshua R. Richter, MD.

, Richter, a hematologist/oncologist specializing in multiple myeloma at John Theurer Cancer Center, discussed the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

OncLive: What is the incidence and survival impact of self-reported symptoms and psychological distress among patients with multiple myeloma?

Richter: The landscape of multiple myeloma is changing. There are many new developments. We are pushing the field forward in terms of how we treat the disease and we are improving outcomes in both the upfront and the relapsed/refractory settings. There are a lot of data that were presented recently that look at ways that we can maximize efficacy of different regimens in relapsed/refractory multiple myeloma. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication